SITC Resource Library

High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute

21 days ago

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article detailing how the University of Pittsburgh Cancer Institute implemented a protocol for the administration of HD IL-2 in a non-ICU oncology specialty setting in 1994. To provide estimates of the toxicity and efficacy of this method of administration, they conducted a retrospective analysis of response, survival and toxicity data of 243 advanced melanoma patients treated with HD IL-2 between 1992 and 2015. Authors: Diwakar Davar, Fei Ding, Melissa Saul, Cindy Sander, Ahmad A. Tarhini, John M. Kirkwood and Hussein A. Tawbi JITC(2017) 5:74

#2017 #JITCPublication #Researcher #SkinCancer #Cytokines #ImmuneCheckpointInhibitors #Article #Advanced #Biomarkers

0 Favorited
0 Files

Tags and Keywords

Related Entries and Links

No Related Resource entered.